IgG class anti-cardiolipin antibody as a possible marker for evaluating fetal risk in patients with systemic lupus erythematosus

J Autoimmun. 1989 Dec;2(6):843-9. doi: 10.1016/0896-8411(89)90010-3.

Abstract

To identify the correlation between incidence of anti-phospholipid antibodies and fetal prognosis in pregnant SLE patients, we measured the amount of anti-cardiolipin antibody in their sera, using solid-phase enzyme immunoassay (EIA) methods. Findings in the group having poor obstetric results (fetal loss group) and in those with a history of full-term births (live birth group) were compared with regard to other anti-phospholipid antibodies. The incidence of IgG class anti-cardiolipin antibody was 60% in the fetal loss group and 19% in the live birth group, (P less than 0.05). The incidence of the other anti-phospholipid antibodies, including lupus anticoagulant and biological false-positive serological test for syphilis (BFP-STS), did not differ significantly between the two groups. Therefore, the presence of IgG class anti-cardiolipin antibody may prove to be a useful marker for evaluating fetal risk in SLE patients.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers
  • Blood Coagulation Factors / immunology
  • Cardiolipins / immunology*
  • Cardiolipins / metabolism
  • Chi-Square Distribution
  • Female
  • Fetus
  • Humans
  • Immunoenzyme Techniques
  • Immunoglobulin G / analysis
  • Immunoglobulin G / immunology*
  • Lupus Coagulation Inhibitor
  • Lupus Erythematosus, Systemic / immunology*
  • Pregnancy
  • Pregnancy Complications / immunology*
  • Pregnancy Outcome*
  • Risk Factors
  • Syphilis Serodiagnosis

Substances

  • Biomarkers
  • Blood Coagulation Factors
  • Cardiolipins
  • Immunoglobulin G
  • Lupus Coagulation Inhibitor